Business, energy, technology, markets and global industry news from Business News Today

European Commission

PharmaDeviceNews European Commission
Allergan Aesthetics’ European approval for Boey introduces a rapid-onset, short-duration neurotoxin option for treating moderate to severe frown lines. Representative image.
Pharma & Biotech

Boey can show results in hours and fade in weeks: Why AbbVie is betting shorter can be better

AbbVie wins European approval for Boey, a rapid-onset neurotoxin lasting two to three weeks, opening a new test of aesthetics demand.

Read More
Representative image: Tepkinly’s European approval expands bispecific antibody treatment options for adults with relapsed or refractory follicular lymphoma, potentially reshaping second-line lymphoma care.
Pharma & Biotech

Genmab and AbbVie secure EU approval for Tepkinly in relapsed follicular lymphoma

Discover how Tepkinly’s EU approval could reshape second-line follicular lymphoma treatment and the safety and access questions still ahead.

Read More
Representative image: Enhertu’s EU tumor-agnostic approval highlights how HER2 testing and precision oncology diagnostics could shape treatment access for advanced solid tumors.
Medical Devices & Diagnostics

Enhertu wins EU tumor-agnostic approval, but HER2 testing will decide its real impact

The European approval takes Enhertu beyond organ-specific oncology, although its clinical reach will depend on reliable HER2 testing, reimbursement and safety management.

Read More
Representative image: An oncologist reviews lung scan images in a modern cancer care setting, reflecting Amgen’s EU approval for Imdylltra in relapsed extensive-stage small cell lung cancer.
Pharma & Biotech

Why Amgen’s Imdylltra EU approval could reshape second-line small cell lung cancer treatment

Find out how Amgen’s Imdylltra EU approval could change relapsed small cell lung cancer treatment across Europe.

Read More
Representative image of an oncologist reviewing lung cancer scans in a modern treatment room, reflecting Amgen’s European approval for Imdylltra and the growing shift toward bispecific antibody therapies for extensive-stage small cell lung cancer.
Pharma & Biotech

Is Amgen’s bispecific lung cancer drug becoming a global standard after chemotherapy failure?

Amgen’s Imdylltra has European approval in relapsed small cell lung cancer. Survival data now face reimbursement and adoption tests.

Read More
Representative image: A clinician reviews bladder cancer imaging in a modern oncology setting, reflecting Merck’s KEYTRUDA plus Padcev EU regulatory milestone for cisplatin-ineligible muscle-invasive bladder cancer patients.
Pharma & Biotech

Why Merck’s CHMP win for KEYTRUDA plus Padcev matters in muscle-invasive bladder cancer

Merck’s bladder cancer push is moving earlier in Europe. KEYTRUDA plus Padcev could reset cisplatin-ineligible MIBC care.

Read More
Representative image: A haematology consultation illustrates how PYRUKYND’s European Union approval for adults with thalassaemia could shift attention toward oral rare blood disease treatments, patient access and reimbursement across Europe.
Pharma & Biotech

Could Agios and Avanzanite turn PYRUKYND into Europe’s next rare blood disease launch test?

PYRUKYND has EU approval in thalassaemia. Now Agios and Avanzanite face Europe’s harder test: access, uptake and reimbursement.

Read More
Representative image: A healthcare professional prepares a subcutaneous injection in a clinical setting, reflecting the treatment shift highlighted by Pfizer’s Hympavzi EU indication expansion for hemophilia A and hemophilia B patients with inhibitors.
Pharma & Biotech

EU backs Pfizer’s Hympavzi for hemophilia patients with inhibitors. What changes now?

Hemophilia care is moving beyond factor replacement. Pfizer’s Hympavzi EU expansion tests how far anti-TFPI therapy can scale.

Read More
Representative image: A clinical consultation for psoriatic arthritis, highlighting how Bristol Myers Squibb’s EU approval of Sotyktu could expand oral treatment options for adults with active inflammatory joint disease.
Pharma & Biotech

Why Bristol Myers Squibb’s Sotyktu approval could reshape the oral psoriatic arthritis race

A new EU approval is only the first hurdle. Sotyktu now faces Europe’s tougher test: payer access, sequencing, and real-world uptake.

Read More
Pharma & Biotech

Does Rhythm Pharmaceuticals, Inc. now lead the rare neuroendocrine obesity treatment space?

Discover how Rhythm Pharmaceuticals, Inc.’s EU approval of setmelanotide could redefine rare obesity treatment and what comes next for the market.

Read More